the aid library

LIST OPTIONS

Filter

7531

Download (339)

View PDF (467)

Note technique: Éducation, autonomisation des filles et éradication des mutilations génitales féminines

UN Children's Fund UNICEF (2021) C1

Download (290)

View PDF (532)

Dangerous inequalities: World Aids report 2022

UNAIDS (2022) C_WHO

The world is not on track to end the AIDS pandemic. New infections are rising and AIDS deaths are continuing in too many communities. This report reveals why: inequalities are holding us back. In frank terms, the report calls the world’s attention to the painful reality that dangerous inequalities... more

Download (302)

View PDF (308)

Transgender people and HIV

D. Adams; J. Byrne; M. Cabra; et al. World Health Organization (2015) C_WHO

Policy Brief

Download (276)

View PDF (273)

Special edition: HIV in MSM

I. Steffens; K. Hagmaier; K. Wilson; et al. Eurosurveillance (Europe’s journal on infectious disease epidemiology, prevention and control); European Centre for Disease Prevention and Control (2015) C2

Eurosurveillance Impact Factor 5.7 June 2015 www.eurosurveillance.org Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe

Download (422)

View PDF (643)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (299)

View PDF (471)

Приоритетные аспекты изучения проблемы ТБ/ВИЧ в условиях высокой распространенности ВИЧ-инфекции и ограниченных ресурсов

Delphine Sculier, Haileyesus Getahun, Reuben Granich World Health Organization, TB HIV working group, Stop TB Partnership (2011) C_WHO

Цель этого документа – повысить уровень осознания актуальности приоритетных направлений научных исследований по проблеме ТБ/ВИЧ (то есть по тем направлениям, кот... more

Download (249)

View PDF (302)

Global competency and outcomes framework for universal health coverage

World Health Organization WHO (2022) C_WHO

Download (270)

View PDF (380)

Technical expert meeting on urban health, June 2021: meeting report

World Health Organization WHO (2022) C_WHO

External Link

Strengthening the collection, analysis and use of health workforce data and information: a handbook

World Health Organisation (WHO) (2023) C_WHO

Access to health workers who are fit for purpose, motivated and protected is a fundamental force of health service delivery and the achievement of universal health coverage and the health and health-related Sustainable Development Goals. Data and knowledge of the distribution, skill mix and future d... more

Download (3897)

View PDF (2092)

Knowledge, Attitude And Practice Surveys In Child Protection

The Child Protection Initiative, Save the Children (2013) C2

A step-by-step guide for child protection programmes to the design and implementation of KAP survey methods. In particular, this guide will help to strengthen the quality of our research, monitoring and evaluation work, and enable Save the Children to contribute to a step-change in the child protect... more

Download (301)

View PDF (343)

Providing individualized peer support in mental health and related areas WHO QualityRights training to act, unite and empower for mental health (P I L O T V E R S I O N)

World Health Organization WHO (2017) C_WHO

This document has been developed to support countries develop and strengthen individualized peer support services in mental health and related areas. It addresses the provision of individualized peer support in the context of health services and the wider community.

Download (287)

View PDF (350)

Prevention of Depression and Promotion of Resilience. Consensus Paper

Pim Cuijpers, Laura Shields-Zeeman, Bethany Hipple Walters, Ionela Petrea European Union EU (2016) CC

EU Compass for Action on Mental Health and Well-being

Download (481)

View PDF (686)

When the Drugs Don’t Work – Antibiotic Resistance as a Global Development Problem

The Dag Hammarskjöld Foundation and ReAct (2019) C2

This paper focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment. It presents concrete examples of the underlying and complex aspects of antibiotic resistance and its impacts across different Sustainable Development ... more

External Link

Brazil's health system functionality amidst of the COVID-19 pandemic: An analysis of resilience

Bigoni, A.; et al. (2022) C2

The Lancet Regional health Americas, vol.10 (2022) June 1, March 04, 2022DOI:https://doi.org/10.1016/j.lana.2022.100222

External Link

Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas

Suárez, C., Nolder, D., García-Mingo, A. et al. Research and reports in tropical medicine (2022) CC

Research and Reports in Tropical Medicine 2022:13 25–40. Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with po... more

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Senegal

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr... more

Download (375)

View PDF (477)

Philippines: A Training Manual for Health Workers on Healthy Lifestyle - Promoting Tobacco and Alcohol Free Environment (Module 5/6)

WHO and DOH Philippines (2009) C_WHO

Download (412)

View PDF (537)

Africa CDC Non Communicable Diseases, Injuries Prevention and Control and Mental Health Promotion Strategy
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) CC

Non-communicable diseases (NCDs) & injuries and mental health conditions constitute a serious impediment to achieving the vision of Agenda 2063 to build an integrated, prosperous, and peaceful Africa driven by its own citizens. Each year, these conditions cause millions of premature deaths and disab... more

Download (240)

View PDF (535)

UNODC-WHO Stop-Overdose-Safely (‎S-O-S)‎ project implementation in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine

World Health Organization WHO; United Nations Office on Drugs and Crime UNODC (2021) C_WHO

Summary Report

Download (262)

View PDF (482)

Good Practices in Mental Health and Well-being

European Union EU (2016) CC

Africa CDC Non Communicable Diseases, Injuries Prevention and Control and Mental Health Promotion Strategy recommended

Africa CDC Non Communicable Diseases, Injuries Prevention and Control and Mental Health Promotion Strategy
recommended